Literature DB >> 8521768

Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol.

M J Kendall1.   

Abstract

Fixed dose antihypertensive combinations are being used increasingly in the management of hypertension. There are advantages and disadvantages of this form of therapy. The key aims are to: (i) achieve increased efficacy by using drugs that complement each other's actions; (ii) use low doses to minimise adverse effects; and (iii) provide a simple once daily regimen. Fixed dose combinations containing metoprolol have the advantage that beta-blockers are drugs for which there is most evidence that they are cardioprotective; metoprolol is the best documented beta-blocker in this context. The early combination of conventional release metoprolol and hydrochlorothiazide was inadequately investigated by modern standards, but proved well tolerated and effective in clinical practice. The introduction of the long acting metoprolol CR/ZOK (controlled release/zero order kinetics) produced a very satisfactory once daily preparation with no major pharmacokinetic interactions. The fixed dose combination of felodipine and metoprolol CR/ZOK has been well investigated. The two agents complement each other's actions and together provide very effective blood pressure control, cardioprotection and very good tolerability. A case can be made that this preparation more closely meets the requirements of an ideal antihypertensive than a single agent given alone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521768     DOI: 10.2165/00003495-199550030-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  47 in total

1.  The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a 14/190 metoprolol OROS system.

Authors:  P Lloyd; V A John; M Signy; S E Smith
Journal:  Am Heart J       Date:  1990-08       Impact factor: 4.749

2.  Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects.

Authors: 
Journal:  Circulation       Date:  1972-05       Impact factor: 29.690

3.  Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study.

Authors:  J Wikstrand; G Westergren; G Berglund; D Bracchetti; A Van Couter; C A Feldstein; K S Ming; K Kuramoto; S Landahl; E Meaney
Journal:  JAMA       Date:  1986-03-14       Impact factor: 56.272

4.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

5.  Mono- and combination therapy with felodipine or enalapril in elderly patients with systolic hypertension.

Authors:  L M Wing; A E Russell; A L Tonkin; R W Watts; A J Bune; M J West; J P Chalmers
Journal:  Blood Press       Date:  1994-03       Impact factor: 2.835

6.  Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone.

Authors:  B Dahlöf; L Jönsson; O Borgholst; G Ekblad; C Engstrand; I Grundestam; A Lindh
Journal:  Blood Press Suppl       Date:  1993

7.  Efficacy and tolerability of a fixed combination of metoprolol CR/ZOK 100 mg and hydrochlorothiazide (HCT) 12.5 mg in comparison with the fixed combination of metoprolol and HCT.

Authors:  G Leikersfeldt; S L Rasmussen; B Atmer; S Hjalmers; I Wahlqvist
Journal:  J Clin Pharmacol       Date:  1990-02       Impact factor: 3.126

8.  Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol?

Authors:  M Kendall; S Akhlaghi; B Hughes; H Lewis
Journal:  J Clin Pharmacol       Date:  1990-02       Impact factor: 3.126

9.  Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group.

Authors: 
Journal:  Eur Heart J       Date:  1985-03       Impact factor: 29.983

10.  The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Authors:  K J Hoffmann; C G Regårdh; M Aurell; M Ervik; L Jordö
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

View more
  1 in total

Review 1.  Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.

Authors:  Domenic A Sica
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.